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3-Ketosphinganine provokes the accumulation of
dihydroshingolipids and induces autophagy in
cancer cells†
Yadira F. Ordo´n˜ez,‡a Je`ssica Gonza´lez,‡a Carmen Bedia,§a Josefina Casas,a
Jose´ Luis Abad,a Antonio Delgadoab and Gemma Fabrias*a
Although several reports describe the metabolic fate of sphingoid bases and their analogs, as well as their
action and that of their phosphates as regulators of sphingolipid metabolizing-enzymes, similar studies for
3-ketosphinganine (KSa), the product of the first committed step in de novo sphingolipid biosynthesis, have
not been reported. In this article we show that 3-ketosphinganine (KSa) and its dideuterated analog at C4
(d2KSa) are metabolized to produce high levels of dihydrosphingolipids in HGC27, T98G and U87MG cancer
cells. In contrast, either direct C1 O-phosphorylation or N-acylation of d2KSa to produce dideuterated
ketodihydrosphingolipids does not occur. We also show that cells respond to d2KSa treatment with induction
of autophagy. Time-course experiments agree with sphinganine, sphinganine 1-phosphate and dihydroceramides
being the mediators of autophagy stimulated by d2KSa. Enzyme inhibition studies support that inhibition
of Des1 by 3-ketobases is caused by their dihydroceramide metabolites. However, this eﬀect contributes
to increasing dihydrosphingolipid levels only at short incubation times, since cells respond to long time exposure
to 3-ketobases with Des1 overexpression. The translation of these overall eﬀects into cell fate is discussed.
Introduction
Sphingolipids (SLs) are a major class of constituents of eukaryotic
cell membranes. In addition to a structural role, some sphingo-
lipids are bioactive and control vital biological functions by
regulating signal transduction pathways involved in several
processes (i.e. apoptosis, adhesion, autophagy, cell proliferation,
diﬀerentiation, migration, senescence, etc.).1–12
The regulation of sphingolipid metabolism is critical for
normal cell function and its dysregulation has been implicated in
pathophysiological conditions. Ceramide (Cer), the central molecule
in SL metabolism, can be generated by several mechanisms
including both catabolic and anabolic pathways.1 One catabolic
pathway involves sphingomyelinase-mediated hydrolysis of sphin-
gomyelins. In another catabolic route, complex glycosphingolipids
are degraded by specific hydrolases to monohexosylceramides
(MHCer) (glucosylceramide and galactosylceramide), which are
then hydrolyzed by specific b-glucosidases and galactosidases,
respectively, to produce Cer. Another mechanism is the anabolic
de novo pathway, which begins with the condensation of serine
and palmitoyl-CoA to form 3-ketosphinganine (KSa), a reaction
catalyzed by serine palmitoyltransferase (SPT). Then, 3-keto-
sphinganine reductase (KSR) mediates the reduction of KSa to
sphinganine (Sa), which is transformed into dihydroceramide
(dhCer) through acylation by ceramide synthases (CerS). In the last
step of the de novo pathway, Cer is formed through the introduction
of an (E)-4 double bond into dhCer by dihydroceramide desaturase
(Des1). Once formed, Cer can be degraded through the catabolic
route, which involves N-deacylation to sphingosine (So) by cerami-
dases, further phosphorylation to sphingosine 1-phosphate (S1P)
and final irreversible cleavage by S1P lyase.
The metabolic fate of several free bases has been studied
over the years. Dragusin et al.13 investigated the metabolism of
D-erythro-sphinganine (Sa) in several cell lines and compared it
to that of its stereoisomer safingol (D-threo-Sa). Venkataraman
and Futerman14 compared the metabolism of L-erythro- and
L-threo-Sa in cultured cells and in subcellular fractions. Finally, the
metabolic fates of 1-deoxysphinganine and 1-deoxysphingosine
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have also been examined,15,16 as well as those of o-azidosphin-
gosine17 and o-alkynylsphingosine.18 Although enzymatic conver-
sions of KSa into Sa,19 ketosphingosine20 and sphingosine (So)21
were reported in cell free systems in the early 70s, only the
reduction step has been later extensively confirmed in cell culture.
Surprisingly, putative N-acylation of KSa and further formation of
3-ketodihydrosphingolipids, as well as KSa C1 O-phosphorylation,
have not been analyzed.
On the other hand, the regulation of SL metabolizing-enzymes
by SL metabolites has been reported. For instance, cytosolic S1P
inhibits de novo Cer synthesis,22 which has been recently reported
to occur through negative regulation of SPT by sphingosine
kinase 123 and it inhibits acid sphingomyelinase.24 In addition,
D-erythro-So, but not L-threo-So, decreases SPT activity in primary
cultured cerebellar cells.25
In this article, using both KSa and [4,4-2H2]-KSa (d2KSa), a
dideuterated analog of KSa, we show that the 3-ketobase is used
to produce SLs de novo and directed to the catabolic pathway, both
prior to reduction to Sa (Fig. 1), and that this results in an overall
accumulation of dihydrosphingolipids. Metabolic transformations
by directN-acylation andC1O-phosphorylation do not seem to occur
(Fig. 1). Furthermore, we report that Des1 activity is reduced by short
cell treatment with KSa and d2KSa by their dihydroceramide and/or
ceramide metabolites. Finally, in agreement with previous reports
supporting the role of dhCer as a mediator of autophagy, we show
that autophagy is induced by d2KSa in three diﬀerent cell lines.
Results
3-Ketosphingoid bases induce changes in the sphingolipidome
in HGC27 cells
Cell viability experiments showed that KSa was cytotoxic to
HGC27 cells with CC50 and CC25 values (24 h) of 19.7  3.3 mM
and 12.6  6.4 mM, respectively (mean  SD of three experiments
in triplicate). In these cells, KSa at 5 mM modified sphingolipid
composition and this modification was already significant at
the earliest time point examined (3 h) (Fig. 2). Exogenous KSa
was metabolized to aﬀord high levels of Sa, which decreased
over incubation time (Fig. 2A). Sa was then incorporated into
both the catabolic and the de novo Cer synthesis pathways (see
Fig. 1). Thus, high amounts of Sa 1-phosphate (SaP) were produced
at 3 and 6 h of treatment, to decrease at longer incubation times
(Fig. 2B). On the other hand, Sa was acylated to dhCer, whose
levels reached a maximum at 6 h post-treatment (Fig. 2C).
A similar pattern was observed for dihydrosphingomyelin (dhSM)
Fig. 1 Possible metabolism of exogenous 3-ketosphinganine. The inter-
rogation sign indicates that the reaction has not been demonstrated.
Enzymes are abbreviated as follows: CerS, ceramide synthases; Des1,
dihydroceramide desaturase; GCS, glucosylceramide synthase; SK, sphingosine
kinases; SKR, 3-ketosphinganine reductase; and SMS, sphingomyelin synthase.
Fig. 2 Eﬀect of KSa and d2KSa on sphingolipid levels in HGC27 cells.
Cells were treated with KSa (5 mM), d2KSa (5 mM) or vehicle for specified
time periods and then cells were collected and processed for LC/MS
lipid analysis. All species were analyzed under ESI-positive mode. (A—F)
Natural sphingolipids. (G) Deuterated sphingolipids. Data correspond
to the mean  SD of three independent experiments in triplicate. Lipid
production over the time of treatment was analyzed using the one-
way ANOVA test (A and F, P o 0.0001; B, P o 0.0002; E, P o 0.0003;
D, P o 0.0004; C, P o 0.0017; G/d2Sa and G/d2SaP, P o 0.0001;
G/d2dhCer, P o 0.0002; G/d2dhSM, P o 0.038; G/d2LdhCer,
P o 0.0073; G/d1Cer, P o 0.0136) followed by Bonferroni’s multiple
comparison test. Diﬀerent letters atop the bars denote statistically
significant diﬀerences between means at diﬀerent times at P o 0.05 as
found by this test.
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(Fig. 2D) and lactosyldihydroceramide (LdhCer) (Fig. 2E),¶
although in both cases the diﬀerence between 3 and 6 h was
higher than that for dhCer. Desaturation of dhCer to Cer was
also found to occur with a maximum at 6 h post-treatment
(Fig. 2F). Although MHCer (ESI,† Fig. S1A), LCer (ESI,† Fig. S1B)
and So (ESI,† Fig. S1C) followed a similar tendency, the diﬀerences
were not always statistically significant. Finally, SM did not change
significantly over the time of treatment with KSa (ESI,† Fig. S1D).
These overall data indicate that catabolism of Sa occurs more
rapidly than its incorporation into the de novo pathway for SL
synthesis. In order to obtain a clearer picture of the metabolism
of exogenous KSa, the metabolic transformation of the labeled
KSa analog d2KSa was investigated. The use of this probe allows
discriminating between the metabolites produced from the
exogenous precursor and those already present in cells at the
time of treatment. Labeled sphingolipids produced from d2KSa
followed similar patterns to those found with unlabeled KSa
(Fig. 2G). Thus, prior to reduction to [4,4-2H2] Sa (d2Sa), the
probe was incorporated into the catabolic route to aﬀord high
levels of [4,4-2H2] SaP (d2SaP), which reached a maximum at 3 h.
In contrast, biosynthesis of SLs de novo occurred at later time
points, with [4,4-2H2] dhCer (d2dhCer) exhibiting maximum
levels at 3 and 6 h and [4,4-2H2] dihydrosphingomyelin (d2dhSM)
and [4,4-2H2] lactosyldihydroceramide (d2LdhCer) peaking at 16 h.
Regarding monodeuterated sphingolipids, [4-2H] Cer (d1Cer)
was detected at lower levels than those of natural Cer formed
from KSa (Fig. 2G and F, respectively). This result is in agree-
ment with the reported primary isotope eﬀect in the desaturation
of a 4,4-dideuterated dhCer.26
Putative N-acylation and C1 O-phosphorylation of d2KSa
were also investigated. Selection of ions corresponding to the
deuterated 3-ketosphingolipid analogs (ESI,† Table) did not
provide any evidence for direct N-acylation of d2KSa and further
formation of deuterated ketodihydrosphingomyelins and gluco-
sylketodihydroceramides. Likewise, dideuterated 3-ketosphiganine
1-phosphate was not detected in the chromatograms. An authentic
synthetic sample of N-hexadecanoyl-3-ketosphinganine was used
as standard to predict the expected retention times of the putative
3-ketodihydrosphingolipids. The absence of N-hexadecanoyl-3-
ketosphinganine and dideuterated N-hexadecanoyl-3-ketosphin-
ganine in extracts from cells treated with KSa and d2KSa,
respectively, is shown as an example in ESI,† Fig. S2.
Inhibition of Des1 by the 3-ketobases
Although the above results support that the observed increase
in dihydrosphingolipids provoked by exogenous KSa and d2KSa
was due to their metabolism, the possibility that Des1 was impaired
by the 3-ketobases could not be ruled out. To assess this issue, Des1
activity was measured in both intact cells and cell lysates in the
presence of KSa, d2Ksa or some downstream metabolites.
As shown in Fig. 3A, live cells co-incubated for 4 h with KSa and
the Des1 substrate, namely N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)-
amino]hexanoyl]sphinganine (dhCerC6NBD), produced significantly
less N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]sphin-
gosine (CerC6NBD)27 than controls (EtOH). Des1 inhibition was
also provoked by d2KSa and XM462 (positive control). However,
when cells were treated with the probes for 24 h and then with
the substrate for 4 additional hours, significantly higher desaturation
occurred in cells treated with d2KSa than with KSa, which was not
significantly diﬀerent from controls (Fig. 3B). XM462 showed Des1
inhibitory activity, proving that the enzyme is active and responds to
inhibition under the experimental conditions of the assay. These
results suggested that long time treatment with d2KSamight induce
overexpression of Des1. To judge this possibility, Des1 mRNA from
cells exposed to d2KSa, KSa and the vehicle for 24 h was determined
by qPCR. As shown in Fig. 3C, significantly higher Des1mRNA levels
were present in cells treated with d2KSa than with the vehicle.
Although the Des1 transcript also increased after treatment with
KSa, this increase was only marginally significantly diﬀerent
from controls (P = 0.058). These results support that although
Des1 inhibition may contribute to the accumulation of dihydro-
sphingolipids brought about by the 3-ketobases at short time
points, impaired Des1 activity does not contribute to increase
dihydrosphingolipid levels at long incubation times.
Fig. 3 Eﬀect of KSa and d2KSa on Des1 activity and expression. Inhibition
was determined in both intact cells (A and B) and cell lysates (D) by
measuring the desaturation of dhCerC6NBD (10 mM) to CerC6NBD.27 (A)
Intact cells were incubated for 4 h with the substrate together with KSa
(5 mM), d2KSa (5 mM), XM462 (10 mM) (positive control of inhibition) or
ethanol (control). (B) Intact cells were incubated for 24 h with KSa (5 mM),
d2KSa (5 mM), XM462 (10 mM) (positive control of inhibition) or ethanol
(control), and then the substrate was added and further incubated for 4 h.
(D) The assay in cell lysates was carried out by incubation of protein (equivalent
to 106 cells per replicate) and the substrate in the absence (EtOH, vehicle) or
presence of 10 mM of test compounds and 120 mM of NADH as reported.27 In
all cases, the formation of CerC6NBD was determined by HPLC coupled to a
fluorescence detector. Data correspond to the mean  SD of three (A and B)
or six (D) independent experiments in triplicate. Data were analyzed by one-
way ANOVA followed by Bonferroni’s multiple comparison post-test. In all
cases, ANOVA P o 0.0001. Diﬀerent letters denote statistically significant
diﬀerences between means at P o 0.05 as found by this test. (C) Eﬀect of
KSa (5 mM/24 h) and d2KSa (5 mM/24 h) on the mRNA levels (as determined
by quantitative real-time PCR) of Des1. Data correspond to the mean  SD
of three independent experiments in duplicate. Data were analyzed by
one-way ANOVA followed by Bonferroni’s multiple comparison post-test.
ANOVA P o 0.01. Diﬀerent letters denote statistically significant diﬀerences
between means at P o 0.05 as found by this test.
¶ Monohexosyldihydroceramides, both natural and deuterated, and monodeuterated
monohexosylceramides cannot be analysed accurately because of the interference of
highly abundant sphingomyelins.
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The eﬀect of KSa and d2KSa on Des1 in a cell-free system
was also analyzed. Since lipid analysis showed the formation
of diverse metabolites in cells, the Des1 inhibitory activity of
downstream sphingolipid metabolites was also determined. As
shown in Fig. 3D, neither KSa nor d2KSa reduced Des1 activity.
Likewise, Des1 was not inhibited by Sa and SaP. However, both
N-octanoylsphinganine (C8dhCer) and N-octanoylsphingosine
(C8Cer) reduced Des1 activity to 70 and 60% of control, respectively,
at equimolar concentrations with the substrate. In these experi-
ments, XM462 elicited Des1 inhibitory activity, proving that the
enzyme is active and responds to inhibition under the experimental
conditions of the assay. These results support that dhCer and/or Cer
are the actual Des1 inhibitory species in intact cells subjected to
short time treatments with the 3-ketobases (Fig. 3A).
Physiological eﬀect of 3-ketosphingoid bases
We previously reported that 4,4-dideuterated dhCer induced
autophagy in HGC-27 cells and that this induction was preceded
by an increase in d2dhCer of diﬀerent chain lengths.28 This result
supported a connection between dhCer increase and autophagy.
Since both KSa and d2KSa induce an increase in dhCer,
we investigated whether autophagy was also activated by the
3-ketosphingoid bases. For an unambiguous interpretation of
results, these experiments were carried out with d2KSa because
this compound induces an increase in d2dhCer (Fig. 2G) with
no increase in natural Cer levels (Fig. 2F) and a poor increase in
monodeuterated Cer levels (Fig. 2G), while both dhCer (Fig. 2C)
and Cer (Fig. 2F) augment in treatments with KSa. As shown in
Fig. 4A and B, HGC27 cells treated with 12 mM d2KSa for 6 h
exhibited a significant rise in the levels of LC3-II over controls
and this increase was enhanced by co-incubation with protease
inhibitors, which block the degradation of proteins included in
the autophagolysosome. These results support that d2KSa
stimulates the autophagic flux. However, LC3-II did not augment
in cells treated with 12 mM d2KSa for 24 h (data not shown), but
cells exhibited signs of apoptotic cell death (Fig. 4C and D).
However, other experiments using diﬀerent techniques must be
carried out to confirm the apoptosis outcome. In order to deter-
mine the scope of the proautophagic action of the 3-ketobases, the
d2KSa activity at increasing LC3-II levels was also determined in
two glioblastoma cell lines. Western blot analysis of proteins from
T98G cells treated with d2KSa (12 mM)8 for 6 h showed increased
levels of LC3-II as compared to controls treated with the vehicle.
Moreover, this increase was enhanced in the presence of protease
inhibitors (Fig. 5A and C). Similar results were found in U87MG
cells upon exposure to d2KSa (20 mM/6 h)8 (Fig. 5E and G). With
these cells, immunofluorescence studies with an antibody that
recognizes preferentially the lipidated form of endogenous LC3
revealed an increased accumulation of immunostained LC3-II
puncta in cells treated with the compounds (Fig. 5B and F),
indicating that d2KSa induces autophagosome formation.
Importantly, under conditions found to induce autophagy,
d2KSa modified the sphingolipidome in both cell lines. As
found with HGC27 cells (see above), d2KSa provoked an increase
in d2dhCer, d2dhSM and d2LdhCer levels. Also similarly to
HGC27 cells, the levels of d1Cer (Fig. 5D and H) were lower than
the levels of Cer (ESI,† Fig. S3), likely due to a primary kinetic
isotope eﬀect at C4 in the Des1-catalyzed reaction.26 In contrast
to HGC27 and U87MG cells, T98G cells produced very low
amounts of d2SaP (Fig. 5D), indicating either that phosphorylation
is very rapid and no longer evident at 6 h after treatment or that
sphingosine kinases are poorly active in these cells under the
experimental conditions of the assay. These overall results indicate
that d2KSa stimulates the production of dihydrosphingolipids and
the autophagic flux also in T98G and U87MG cell lines, supporting
that these eﬀects are not cell specific. In contrast to HGC27 cells,
increasing d2KSa incubation time did not result in apoptosis in
T98G and U87MG cells (ESI,† Fig. S4), but in an increased
number of necrotic cells (positive to propidium iodide, but not
to Annexin V, staining) as compared to vehicle treated controls.
Early and late apoptosis were induced by N-octanoylsphingosine
(C8Cer), which was used as positive control of the apoptotic
response in these cells.
Discussion
Although several reports describe the metabolic fate of sphingoid
bases and their analogs,13,14,16,17 as well as their action and that of
their phosphates as regulators of sphingolipid metabolizing
enzymes,22–25 similar studies for KSa, the product of the first
committed step in sphingolipid biosynthesis, have not been
reported. Using both natural KSa and mass labeled d2KSa, in
Fig. 4 Eﬀect of d2KSa in HGC27 cells. Cells were treatedwith 12 mMd2KSa for
either 6 h (A and B) or 24 h (C and D). In (A) and (B), treatments were carried out
in the absence (PI) or presence (+PI) of protease inhibitors. Cells were lysed
and proteins were analyzed by the Western blot technique using an anti-LC3
antibody. (A) Western blot image corresponding to one representative experi-
ment. (B) Histograms showing the relative fold-changes of LC3-II/Actin over
control (EtOH). In (C) and (D), cells were processed and analyzed by flow
cytometry after propidium iodide/FITC-Annexin V staining. (C) Representative
cell distribution plots. (D) Histogram showing the percentage of alive, apoptotic
and necrotic cells. Data correspond to three experiments in duplicate (A and B)
or triplicate (C and D). In (B), data were analyzed by the one-way ANOVA test
(Po0.0001) followed by Bonferroni’s multiple comparison test. Diﬀerent letters
denote statistically significant diﬀerences between means at Po 0.05 as found
by this test. In (D), asterisks indicate statistical significance vs. vehicle at Po 0.05
(unpaired two-tailed t test).
8 Concentrations used according to cell viability data. d2KSa was cytotoxic to
T98G and U87MG cells with CC50 values (mean  SD, 3 experiments with
triplicates) at 24 h of 26.9 mM (4.2) and 29.9 mM (9.1), respectively, and CC25
values (24 h) of 16.9 mM (7.6) (T98G) and 15.0 mM (4.9) (U87MG).
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this article we show that exogenous KSa follows the expected
metabolic pathways being directed to the catabolic route and
used to produce SLs de novo, both prior to reduction to Sa.
Furthermore, previously unreported direct N-acylation of d2KSa
and C1 O-phosphorylation have not been found to occur. These
results may indicate that CerS and sphingosine kinases do not
accept KSa as substrate. However, this does not agree with the
reported ability of CerS to accept a wide range of sphingoid
bases as substrates, including fumonisins,29,30 deoxysphingoid
bases,16,31 azidosphingoid bases17 and jaspine B (Cingolani et al.,
manuscript in preparation). On the other hand, sphingosine
kinases have also been found to phosphorylate several unnatural
sphingoid bases, such as, for instance, the immunomodulatory
sphingolipid analog FTY720.32,33 A more plausible explanation is
that KSa is readily reduced to Sa as soon as it is available, either
from exogenous sources or endogenously generated by SPT action,
so that sufficient amounts of the ketobase substrate are never
accessible for CerS- and SK-mediated transformation. The fact
that free KSa was not detected in lipid extracts, while very high
amounts of Sa, its reduction product, were found at early time
points supports the fast reduction hypothesis.
Lipid analysis and Des1 activity studies support that Des1
inhibition by substrates (dhCer or d2dhCer) may contribute to
the accumulation of dihydrosphingolipids brought about by
the 3-ketobases in the first hours of treatment, but not in long
incubation times. This conclusion is based on the findings that
only C8dhCer and C8Cer, but not KSa, Sa and SaP, decrease
Des1 activity in cell lysates. Furthermore, although C8Cer inhibits
Des1 in cell lysates and ceramide levels increase in treatments with
KSa, d2KSa is a more potent Des1 inhibitor in cell lysates but
deuterated ceramide levels increase poorly in treatments with
d2KSa. The latter finding is against Cer being the Des1 inhibitory
species in treatments with the 3-ketobases. Finally, the 3-ketobases
lowered Des1 activity in intact cells only in co-incubation with
the Des1 substrate for a short time period, but not after long pre-
incubation times. Interestingly, the latter conditions resulted in
increased Des1 expression, mainly in d2KSa treatments, in which
augmented Des1 activity was also evidenced. Increased Des1
expression likely occurs as a response of cells to the accumulation
of dhCer at long incubation times with the 3-ketobases. The higher
overexpression provoked by d2KSa as compared to natural KSa can
be explained considering that d2KSa is metabolically converted
into d2dhCer, which is desaturated at a 7-fold lower rate than
natural dhCer.26 Higher overexpression of Des1 would be induced
by d2dhCer rather than by dhCer (formed from exogenous KSa) to
cope with the enzyme clogging provoked by the slowly processed
deuterated substrate.
Both Cer and dhCer have been reported to exhibit important
biological functions. While the roles of Cer in mediating
antimitogenic actions have been recognized for a number of
years,1–4,34–37 the biological actions of dhCer have been disclosed
more recently.5 They include induction of cell cycle arrest,38
delay28 and autophagy39–44 and inhibition of Cer-induced channel
formation in mitochondria with final mitigation of the apoptotic
effect of Cer.45 In addition to both amides, phosphorylated
sphingolipids such as long chain base 1-phosphates8–11,46–47
and Cer 1-phosphate12,48,49 are also biologically active. In the
first case, experimental evidence supports the idea that the
location of S1P production dictates its functions. Thus, while
S1P generated in the cytosol by the action of sphingosine kinase 1
stimulates cell proliferation and inhibits de novo Cer synthesis,
S1P produced in the ER by sphingosine kinase 2 promotes Cer
synthesis through the salvage pathway and induces apoptosis.22 In
this article we report that d2KSa induces autophagy at short
incubation times, when a large increase in Sa, SaP and dhCer
occurs, but not at long incubation times, when those dihydro-
sphingolipids undergo a significant decrease. In contrast, dhSM
and dhLCer experienced the highest increase at long incubation
times, when autophagy was no longer induced by d2KSa, arguing
against the role of both lipids in autophagy induction by d2KSa.
This correlation supports the argument that Sa, SaP and/or dhCer
are involved in the pro-autophagic activity of d2KSa. Autophagy
Fig. 5 Eﬀect of d2KSa on autophagy and deuterated lipid levels in glioblastoma
cells. Autophagy was determined by Western blot (A, C, E, G) and immuno-
fluorescence (B and F) analysis of LC3-II in T98G (A–C) and U87MG (E–G) cells
treated with d2KSa (A, 12 mM/6 h; B, 20 mM/6 h) or vehicle in the presence or
absence of protease inhibitors (PI: E64D and Pepstatin A) as detailed in the
Experimental section. (A and E) Western blot images corresponding to repre-
sentative experiments. (B and F) Representative fluorescencemicroscopy images
showing the formation of LC3-II puncta in T98 (B) and U87 (F) cells after
treatment with d2KSa (B, 12 mM/6 h; F, 20 mM/6 h) or vehicle. Scale bar: 10 mm.
(C and G) Histograms showing the relative fold-changes of LC3-II/Actin over
control (EtOH) in WB analyses. (D and H) Deuterated sphingolipids present in
T98G (D) and U87MG (H) cells treated with d2KSa (A, 12 mM/6 h; B, 20 mM/6 h).
Data correspond to three experiments in duplicate (A–C and E–G) or triplicate
(D and H). In (C), (D), (G) and (H) data were analyzed by the one-way ANOVA test
(P o 0.0001 in all cases) followed by Bonferroni’s multiple comparison test.
Different letters denote statistically significant differences between means at
Po 0.05 as found by this test.
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activation by dhCer5–7,41 and Sa42,50 has been reported and our
results add further support to the role of both sphingolipids as
mediators of autophagy. Cer and S1P have also been reported to
stimulate autophagy.51 However, Cer and S1P (data not shown) do
not increase upon d2KSa treatment over controls, which does not
support the role of both species asmediators of autophagy induction
by d2KSa treatment. Regarding SaP, although differential effects of
SaP versus S1P have been described,9–11 SaP has never been reported
to induce autophagy. Although d2SaP also increases in parallel with
autophagy induction by d2KSa in HGC27 and U87MG cell lines,
such an increase is not observed in T98G cells, while autophagy is
also stimulated in these cells. These results are against SaP being
involved in autophagy induction.
Although autophagy is activated as a cell survival response to
harmful stimuli, cells can eventually die if the pro-autophagic
input is severe or long lasting. Resveratrol has been shown to
induce autophagy without any sign of cell death in HGC27 cells
with the preferential production of C16dhCer.28 On the other
hand, sphingolipidomic analyses of four T-cell acute lympho-
blastic leukemia cell lines revealed strong positive correlations
between cytotoxicity associated with increased autophagy and
levels of C22 and C24dhCer.43 Moreover, Sa has been reported
to induce autophagic cell death42,50 and also to mediate the
cytotoxicity of fumonisin B152 and fenretinide.53 We speculate
that in our cell models, d2KSa exhibits cytotoxicity because the
balance between protective (C16d2dhCer) and cytotoxic (d2Sa,
C22d2dhCer and C24d2dhCer) species is tilted toward the
latter. Further studies are ongoing to study the role of diﬀerent
sphingolipid species in autophagy induction and outcome.
Materials and methods
Materials
Minimum essential medium (MEM), Dulbecco’s modified Eagle’s
medium (DMEM), fetal bovine serum (FBS), penicillin/streptomycin,
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT),
BSA, Trypsin–EDTA, non-essential amino acids, NADH, and
pepstatin A were purchased from Sigma. E64D was from Enzo
and the polyvinylidene difluoride (PVDF) membrane was from
Roche. ECL Prime Western Blotting Detection Reagent was
purchased from GE Healthcare. The Annexin V-FITC Early
Apoptosis Detection Kit was purchased from Cell Signaling.
Internal standards for lipidomics were from Avanti Polar Lipids.
Laemmli buffer and acrylamide were from BioRad, and SDS
was from Fluka. Antibodies: anti-LC3 was purchased from
Abcam (reference Ab48394), b-actin was from Sigma (reference
A2228) and HRP-secondary antibodies were from GE Healthcare
(anti-mouse, reference RPN4201V; anti-rabbit, reference NA934V).
Compounds KSa, d2KSa, dhCerC6NBD27 and XM46227 were
synthesized in our laboratories.
Synthesis of KSa and d2KSa
KSa was prepared following a reported protocol.54
(2S) 2-Amino-4,4-dideutero-3-oxo-1-octadecanol (HCl salt)
(d2KSa). This compound was prepared by oxidation (pyridinium
dichromate in CH2Cl2) of an erythro/threo mixture of (2S) tert-
butyl 4-(1-hydroxy-2,2-dideuterohexadecyl)-2,2-dimethyloxazolidine-
3-carboxylate,26 followed by acid hydrolysis (HCl in MeOH,
generated by the addition of acetyl chloride to a MeOH solution
of the above precursor). 1H NMR (400 MHz, CD3OD): d 4.23–3.90
(m, 2H), 3.32 (broad, 1H), 1.61 (broad, 2H), 1.30 (broad, 24H),
0.90 (s, 3H). 13C NMR (100 MHz, CD3OD): d 195 (CO), 62.1 (CH),
60.3, 33.1, (30.8–30.4), 30.0, 24.1, 23.7 (CH2), 14.4 (CH3). HRMS
calculated for C18H35D2NO2, 302.3028; found, 302.3032.
N-Hexadecanoyl-3-ketosphinganine55. This standard was
synthesized by acylation of KSa with hexadecanoic acid in the
presence of DCC, Et3N, HOBc, following a standard protocol.
56
1H NMR (400 MHz, CDCl3): d 6.59 (broad d, 1H, NH amide),
4.58 (m, 1H, C2H), 3.91 (m, 2H, C1H), 2.55 (m, 2H, C4H2), 2.26
(t, 2H, C20H2), 1.61 (broad, 4H, C5H2 and C03H2), 1.23 (broad,
24 H), 0.86 (t, 2  CH3). 13C NMR (100 MHz, CDCl3): d 207.8,
174.4, 63.5 (C1), 60.9 (C2), 40.0 (C4), 36.5 (C20), 32.1, 29.8–29.3,
25.7, 23.7, 22.9 (C17 and C150), 14.1 (C18 and C160).
Cell culture
The human gastric cancer cell line HGC 27 was cultured at 37 1C
in 5% CO2 in minimum essential medium supplemented with
10% fetal bovine serum, 1% nonessential amino acids, and
penicillin (100 U ml1) and streptomycin (100 mg ml1). Cells
were routinely grown to a maximum confluence of 60%. Human
glioblastoma cell lines T98G and U87MG were cultured at 37 1C
in 5% CO2 in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum and penicillin (100 U ml1) and
streptomycin (100 mg ml1).
Cell viability
Cell viability was measured in triplicate samples by the MTT assay.
Cells were seeded in 96 well plates at a density of 1 105 cells perml
and then subjected to various treatments for 24 h. At the end of the
treatments MTT was added to each well and incubated for 3 h. The
supernatant was aspirated, and the formazan crystals were dissolved
in DMSO. Absorbance was measured at 570 nm.
LC3-II analysis by Western blot
For LC3-II protein analysis 1  105 cells were plated in 6 well
plates and were allowed to adhere for 24 h. Cells were pre-incubated
with protease inhibitors (E64D 10 mg ml1 and Pepstatin A
5 mg ml1). After 2 h, cells were treated with d2KSa at the
specified concentrations or EtOH as control for 6 h. After treatments,
cells were directly lysed in Laemmli sample buﬀer and heated at
95 1C for 5 min. Samples were loaded onto a 12% polyacrylamide
gel, separated by electrophoresis at 140 V/1 h and transferred onto
a PVDF membrane (100 V/1 h). Unspecific binding sites were then
blocked with 5% milk in TBST (LC3) or 3% BSA in TBST (Actin).
Anti-LC3 antibody was diluted 1 : 1000 in 5% milk in TBST.
Anti-Actin antibody was diluted 1 : 2000 in 3% BSA in TBST.
Membranes were incubated overnight at 4 1C under gentle agitation.
After washing with TBST, membranes were probed with the
corresponding secondary antibody for 1 h at room temperature
(LC3: anti-rabbit diluted 1 : 1000 in 3% BSA in TBST; Actin : anti-
mouse diluted 1 : 10 000 in 5% milk in TBST). Antibody excess
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was eliminated by washing with TBST, and protein detection
was carried out using ECL andmembrane scanning with a LI-COR
C-DiGits Blot Scanner. Band intensities were quantified using
LI-COR Image Studio Lite Software.
Immunofluorescence
Cells were grown on coverslips in 6 well plates at a density of
1  105 cells per ml and allowed to attach. The medium was
replaced with freshmedium containing d2KSa (T98 cells, 12 mM/6 h;
U87MG cells, 20 mM/6 h) or vehicle (EtOH). After treatments cells
were washed with PBS and fixed in 4% paraformaldehyde (25 1C/
20 min). After washing the cells with PBS, aldehydes were quenched
with 50mMNH4Cl in PBS for 10min. Cells were washed again with
PBS, and permeabilized and blocked with 3% BSA/0.1% Triton
X-100 in PBS (25 1C/30 min). After washing with PBS, cells were
incubated with 40 mg ml1 of anti-LC3 antibody in PBS overnight at
4 1C. Following incubation, cells were washed and treated with FITC
conjugated secondary antibody diluted 1 :100 in PBS (25 1C/1.5 h).
The punctate pattern of LC3 was visualized under a Nikon Eclipse
90i fluorescence microscope at 60 objective magnification.
Apoptosis
Cells were seeded in 6 well plates (1  105 cells per ml), and
after 24 h, they were treated for 24 h with either d2KSa at the
specified concentrations or EtOH (negative control). After treat-
ments, cells were collected by trypsinization, washed twice with
PBS and centrifuged (200 rpm/3 min). The cell pellet was
resuspended in 96 mL of Annexin V binding buﬀer, 1 mL of
FITC-Annexin V and 12.5 mL of propidium iodide. After 10 min
on ice in the dark, apoptosis was determined using a Guava
easyCyteTM flow cytometer (Merck Millipore).
Lipid analyses
Cells were seeded at 1  105 cells per ml in 6 well plates (1 ml per
well) and were allowed to adhere for 24 h. The medium was
replaced with fresh medium containing the test compounds at the
specified concentrations or EtOH as control. After specified time
periods, the medium was removed; cells were washed with 400 ml
PBS and harvested with 400 ml Trypsin–EDTA and 600 ml of
medium. Sphingolipid extracts, fortified with internal standards
(N-dodecanoylsphingosine, N-dodecanoylglucosylsphingosine,
N-dodecanoylsphingosylphosphorylcholine, C17-sphinganine and
C17-sphinganine 1-phosphate, 0.2 nmol each), were prepared and
analysed as reported by UPLC-TOF MS.40
Des1 activity assay
The eﬀect of compounds on Des1 activity was studied in both
HGC27 cell lysates and intact cells as reported.40
Quantitative RT-PCR
Total RNA was isolated from cells using the RNeasys Mini Kit
from the QIAGEN protocol. RNA concentration was measured
by spectrophotometric absorption at 260 nm using a NanoDrop
ND-8000 spectrophotometer. RNA was treated with DNAse I to
remove genomic DNA contamination. Quantities from 1 mg to
100 ng of DNAse I-treated RNA were retrotranscribed to cDNA
using Superscripts II Reverse Transcriptase from Invitrogen
and stored at 20 1C. cDNA preparations were used to quantify
specific transcripts in a LightCyclers 480 Real Time PCR System,
using SYBRsGreen Mix (Roche, Germany) and the following
pairs of primers: Des1 (F, 50-CTATGCGTTTGGCAGTTGCA-30, and
R, 50-CAGTTGCCAAAGGCAGCATT-30) and GAPDH (F, 50-ACCATCTT
CCAGGAGCGAGA-30, and R, 50-GATGGCATGGACTGTGGTCA-30).
For all genes, the initial PCR steps were: 10 min at 95 1C, followed
by 45 cycles of 10 s melting at 95 1C and 30 s annealing/extension at
60 1C. The final step was 1 min incubation at 60 1C. All reactions
were performed in triplicate. Relative mRNA abundances of the
diﬀerent genes were calculated from the second derivative
maximum of their respective amplification curves (Cp, calculated
in duplicate). Cp values for target genes (Tg) were compared to the
corresponding values for the GAPDH reference gene to obtain the
DCp values (DCp = CpGAPDH  CpTg).
Conclusions
In conclusion, we have reported that KSa and its deuterated
analog d2KSa induce the production of high levels of dihydro-
sphingolipids resulting from both the probe metabolism and,
under certain conditions, inhibition of Des1 activity. Time-course
experiments show that, among the several dihydrosphingolipids,
Sa/d2Sa, SaP/d2SaP and dhCer/d2dhCer reach maximum levels at
the earliest time points examined (3 and 6 h), while dhSM/d2dhSM
and LdhCer/d2LdhCer increase at longer incubation times (16 and
24 h). Autophagy induction by d2KSa, which occurs at short (6 h) but
not long (24 h) times of d2KSa treatment, correlates with Sa and
dhCer being the mediators of autophagy stimulated by d2KSa.
Finally, we could not find any evidence for the direct N-acylation
or C1 O-phosphorylation of KSa.
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